GLP-1 Coach Blog
Research summaries, practical guides, and honest advice for your GLP-1 journey.
- September 12, 2026·9 min read
The FDA's 2026 Crackdown on Compounded GLP-1s: What It Means If You're on One
A timeline of the FDA's 2025–2026 actions on compounded semaglutide and tirzepatide, and what it actually means if you're currently on one.
Read article → - September 6, 2026·7 min read
Best GLP-1 Tracker & Coaching Apps in 2026
An honest look at the crowded GLP-1 tracker category — Shotsy, MeAgain, Regimen, and others — with one verified standout feature per app.
Read article → - August 28, 2026·8 min read
Switching from Semaglutide to Tirzepatide: Ozempic/Wegovy to Zepbound/Mounjaro
SURMOUNT-5 showed tirzepatide outperforming semaglutide head-to-head. Here's why people switch and how re-titration actually works.
Read article → - August 26, 2026·7 min read
Electrolytes and GLP-1: Why GI Side Effects Put Sodium, Potassium & Magnesium at Risk
Nausea, vomiting, and diarrhea on a GLP-1 cost you more than calories — they cost sodium, potassium, and magnesium. Here's what to watch for.
Read article → - August 26, 2026·5 min read
Introducing the GLP-1 Taper Planner: See Your Own Decay Curve
A new free tool that turns the taper-vs-cold-turkey decision into a picture: your medication level, projected week by week, for stopping now or stepping down.
Read article → - August 23, 2026·6 min read
Shotsy vs GLP-1 Coach: Which Tracker Wins?
An honest side-by-side of Shotsy and GLP-1 Coach — medication coverage, AI coaching, compounded semaglutide support, and who each fits best.
Read article → - August 20, 2026·6 min read
GLP-1 Muscle Loss and Strength: A 2026 Study
A 2026 Cell Reports Medicine study: GLP-1 medications cause some lean mass loss, but relative muscle strength and running performance actually improve.
Read article → - August 20, 2026·6 min read
GLP-1 Plateau: Is It Muscle Loss in Disguise?
When weight stalls on a GLP-1, the real culprit is often inadequate protein and muscle loss. Here's how to tell — and what to do about it.
Read article → - August 14, 2026·9 min read
A1C After Stopping Ozempic: Type 2 Diabetes
For people with type 2 diabetes, stopping a GLP-1 causes A1C to climb back toward pre-treatment levels within weeks to months. Here's what to monitor.
Read article → - August 14, 2026·12 min read
Insurance Dropped Your GLP-1? What to Do Next
Lost GLP-1 coverage? Appeals, patient assistance programs, cash-pay math, formulary alternatives, and honest guidance on compounding — what to try first.
Read article → - August 14, 2026·9 min read
Does Restarting Ozempic After a Break Work?
Restarting a GLP-1 after a break means starting at the lowest dose again. Here's what to expect from the second course and re-titration timeline.
Read article → - August 14, 2026·9 min read
Stopping Mounjaro or Zepbound: What to Expect
SURMOUNT-4 shows stopping tirzepatide causes a ~20-point weight swing over a year. Here's the clearance timeline and why it hits harder than semaglutide.
Read article → - August 14, 2026·9 min read
What Actually Happens When You Stop Wegovy
What the STEP-1 extension trial shows about stopping Wegovy — regain trajectory, timeline, and how it differs from stopping at a lower semaglutide dose.
Read article → - August 13, 2026·10 min read
The First 8 Weeks After Your Last GLP-1 Dose
Week-by-week breakdown of what your body does in the 8 weeks after stopping Ozempic, Wegovy, Mounjaro, or Zepbound. Grounded in clinical data.
Read article → - August 13, 2026·8 min read
GLP-1 Appetite Suppression: How Long It Lasts
Semaglutide takes ~5 weeks to clear; tirzepatide ~3–4 weeks. Here's what the pharmacokinetics tell you about when appetite returns after stopping.
Read article → - August 13, 2026·9 min read
Stopping GLP-1: Why Regain Is Fat, Not Muscle
SURMOUNT-1 DXA data: ~25% of weight lost on tirzepatide was lean mass. Here's what we know — and don't know — about regain composition after stopping.
Read article → - August 13, 2026·10 min read
Tapering Off GLP-1: Cold Turkey vs Step-Down
No FDA taper protocol exists. Here's what tapering a GLP-1 actually means, why prescribers do it anyway, and how to choose between cold turkey and step-down.
Read article → - August 12, 2026·7 min read
Orforglipron vs Ozempic: Head-to-Head Results
Orforglipron beat oral semaglutide in a Phase 3 trial. Here's what the data means — and why it matters for protein intake and muscle preservation.
Read article → - August 12, 2026·8 min read
Ozempic Titration: What Changes at Each Dose
Ozempic doses step up every 4 weeks — 0.25 mg to 2 mg. Each increase brings a nausea window and higher protein demands. What to expect at every stage.
Read article → - August 7, 2026·5 min read
Ozempic vs Wegovy vs Mounjaro: Side Effects
Semaglutide and tirzepatide cause similar but not identical side effects. How Ozempic, Wegovy, and Mounjaro compare on nausea, energy, and appetite.
Read article → - August 7, 2026·5 min read
Protein Needs on Ozempic, Wegovy & Mounjaro
Protein targets matter more on GLP-1 medications than almost anything else you can track. Here's why, how much you need, and how to hit it when appetite is low.
Read article → - August 7, 2026·5 min read
Life After Ozempic: Maintaining Weight Loss
Stopping a GLP-1 is when most people regain weight — but it doesn't have to be. Here's what changes, why regain happens, and how to protect your results.
Read article → - August 7, 2026·5 min read
Ozempic, Wegovy & Mounjaro: Week-by-Week Guide
A week-by-week breakdown of GLP-1 side effects, energy, and appetite changes — from week 1 nausea to week 12 plateaus. Know what's normal at each stage.
Read article → - August 7, 2026·5 min read
Weight Loss Plateau on GLP-1: Why It Happens
GLP-1 plateaus are common and usually don't mean the medication stopped working. Here's what's actually happening — and what to check first.
Read article →